<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Isozyme diversity loss &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/isozyme-diversity-loss/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 23 Jan 2026 09:04:09 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Isozyme diversity loss &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Breast Cancer’s Metabolic Weaknesses from Isozyme Loss</title>
		<link>https://bioengineer.org/breast-cancers-metabolic-weaknesses-from-isozyme-loss/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 23 Jan 2026 09:03:48 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[**Etiketler:** Isozyme diversity loss]]></category>
		<category><![CDATA[Breast Cancer Metabolism]]></category>
		<category><![CDATA[Isozyme diversity loss]]></category>
		<category><![CDATA[metabolic biomarkers]]></category>
		<category><![CDATA[metabolic vulnerabilities]]></category>
		<category><![CDATA[targeted cancer therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/breast-cancers-metabolic-weaknesses-from-isozyme-loss/</guid>

					<description><![CDATA[In a groundbreaking study published in “Genome Medicine,” researchers have unveiled significant insights into breast cancer biology, particularly focusing on the impact of isozyme diversity loss on tumor metabolism. The study, led by Dr. R. Ding and colleagues, explores the concept of collateral metabolic vulnerabilities that arise as a consequence of altering isozyme expression. This [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319713</post-id>	</item>
	</channel>
</rss>
